Abstract
This study aims to explore the prevalence of Low-carbohydrate diet (LCD) among individuals with cardiovascular-kidney-metabolic (CKM) syndrome and its relationship with prognosis.
Methods The individuals diagnosed with CKM were included from the National Health and Nutrition Examination Survey (NHANES) database between 2009 and 2018. Participants were divided into two groups: those on a LCD and those not on a LCD. Multivariate logistic regression analysis was conducted to assess the factors influencing the choice of LCD among CKM individuals. Kaplan-Meier survival curve analysis and multivariate Cox regression analysis were performed to evaluate the association between LCD and the risk of all-cause mortality. Stratified analysis was performed to assess the consistency of results.
Results A total of 1000 non-CKM (stage 0) individuals and 11,141 CKM individuals (stages 1, 2, 3, and 4) were included. The proportions of individuals on LCD for CKM stages 0, 1, 2, 3, and 4 were 1.16%, 2.49%, 1.94%, 1.24%, and 1.68%, respectively. Multivariate logistic regression analysis indicated that age, and race might influence the choice of LCD among CKM individuals. Multivariate Cox regression analysis revealed that compared to non-LCD individuals, those on LCD had a 62% reduced risk of all-cause mortality (HR = 0.38; 95% CI, 0.15-0.92, P = 0.03). Stratified analysis showed no interaction between LCD and CKM stages (P for interaction < 0.05).
Conclusion The proportion of individuals on LCD in CKM is relatively low. Furthermore, LCD can decrease the risk of all-cause mortality among CKM individuals, regardless of CKM stage.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Science and technology fund of Chengdu Medical College (CYZYB22-02). The research fund of Sichuan Medical and Health Care Promotion institute (KY2022QN0309). Sichuan Provincial Medical Association Youth Innovation Project (Q23021). Health Commission of Sichuan Province Medical Science and Technology Program (24QNMP100). Sichuan Provincial Geriatric Clinical Medicine Research Center (24LHLNYX1-48).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The NHANES project is a survey implemented by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) and has received formal authorization from the Institutional Review Board of the NCHS. This study adheres to the ethical guidelines established by the Declaration of Helsinki of 1964 and its subsequent amendments, and has undergone rigorous approval by the National Center for Health Statistics Research Ethics Review Board. All participants in the survey signed informed consent documents based on a comprehensive understanding of the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.